0001477932-22-004656.txt : 20220624 0001477932-22-004656.hdr.sgml : 20220624 20220624160207 ACCESSION NUMBER: 0001477932-22-004656 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220623 FILED AS OF DATE: 20220624 DATE AS OF CHANGE: 20220624 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: TERRELL JASON BRADLEY MD CENTRAL INDEX KEY: 0001567531 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36833 FILM NUMBER: 221039969 MAIL ADDRESS: STREET 1: 13215 BEE CAVE PARKWAY, STREET 2: SUITE 125, GALLERIA OAKS B CITY: AUSTIN STATE: TX ZIP: 78738 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VOLITIONRX LTD CENTRAL INDEX KEY: 0000093314 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 911949078 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 13215 BEE CAVE PARKWAY, STREET 2: SUITE 125, GALLERIA OAKS B CITY: AUSTIN STATE: TX ZIP: 78738 BUSINESS PHONE: 1 (646) 650-1351 MAIL ADDRESS: STREET 1: 13215 BEE CAVE PARKWAY, STREET 2: SUITE 125, GALLERIA OAKS B CITY: AUSTIN STATE: TX ZIP: 78738 FORMER COMPANY: FORMER CONFORMED NAME: STANDARD CAPITAL CORP DATE OF NAME CHANGE: 19990812 4 1 form4.xml FORM 4 X0306 4 2022-06-23-05:00 false 0000093314 VOLITIONRX LTD VNRX 0001567531 TERRELL JASON BRADLEY MD 13215 BEE CAVE PARKWAY, SUITE 125, GALLERIA OAKS B AUSTIN TX 78738 false true false false Chief Medical Officer Common Stock 2022-06-23-05:00 4 A false 22845 0 A 35145 D Common Stock 2022-06-23-05:00 4 A false 1775 0 A 2730 I By Spouse Stock Option (Right to Buy) 3.40 2022-06-23-05:00 4 A false 42098 0 A 2031-08-03-05:00 Common Stock 42098 64766 D Stock Option (Right to Buy) 3.40 2022-06-23-05:00 4 A false 3270 0 A 2031-08-03-05:00 Common Stock 3270 5030 I By Spouse On August 3, 2021, the reporting person was awarded 35,145 restricted stock units, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect 22,845 restricted stock units vesting. The restricted stock units are further subject to a 2-year time-based vesting schedule, vesting in two installments of 11,423 units and 11,422 units on each of August 3, 2022 and August 3, 2023, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. As reported in April 2022, the rights with respect to the remaining 12,300 restricted stock units subject to the award previously vested and remain subject to time-based vesting. On August 3, 2021, the spouse of the reporting person was awarded 2,730 restricted stock units, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect 1,775 restricted stock units vesting. The restricted stock units are further subject to a 2-year time-based vesting schedule, vesting in two installments of 888 units and 887 units on each of August 3, 2022 and August 3, 2023, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. As reported in April 2022, the rights with respect to the remaining 955 restricted stock units subject to the award previously vested and remain subject to time-based vesting. On August 3, 2021, the reporting person was granted an option to purchase 64,766 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 42,098 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two equal installments of 21,049 shares on each of August 3, 2022 and August 3, 2023, respectively. As reported in April 2022, the rights with respect to the remaining 22,668 shares subject to the award previously vested and remain subject to time-based vesting. On August 3, 2021, the spouse of the reporting person was granted an option to purchase 5,030 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 3,270 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two equal installments of 1,635 shares on each of August 3, 2022 and August 3, 2023, respectively. As reported in April 2022, the rights with respect to the remaining 1,760 shares subject to the award previously vested and remain subject to time-based vesting. /s/ Jason Bradley Terrell MD 2022-06-24-05:00